nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—ESR1—urinary bladder cancer	0.418	1	CbGaD
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—urinary bladder cancer	0.151	0.593	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Thiotepa—urinary bladder cancer	0.0261	0.103	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Fluorouracil—urinary bladder cancer	0.0209	0.0823	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Etoposide—urinary bladder cancer	0.0174	0.0687	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Fluorouracil—urinary bladder cancer	0.0146	0.0574	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Cisplatin—urinary bladder cancer	0.0124	0.0488	CbGbCtD
Medroxyprogesterone Acetate—AR—scrotum—urinary bladder cancer	0.0117	0.168	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Etoposide—urinary bladder cancer	0.00708	0.0279	CbGbCtD
Medroxyprogesterone Acetate—AR—penis—urinary bladder cancer	0.00527	0.076	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—urinary bladder cancer	0.00483	0.019	CbGbCtD
Medroxyprogesterone Acetate—HSD3B2—female reproductive system—urinary bladder cancer	0.00302	0.0435	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Podofilox—Etoposide—urinary bladder cancer	0.00286	1	CbGdCrCtD
Medroxyprogesterone Acetate—NR3C1—urine—urinary bladder cancer	0.00254	0.0366	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—urine—urinary bladder cancer	0.00252	0.0363	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—prostate gland—urinary bladder cancer	0.00233	0.0336	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—seminal vesicle—urinary bladder cancer	0.00197	0.0284	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—urine—urinary bladder cancer	0.00192	0.0277	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—lymph node—urinary bladder cancer	0.00177	0.0255	CbGeAlD
Medroxyprogesterone Acetate—SHBG—prostate gland—urinary bladder cancer	0.00175	0.0253	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—smooth muscle tissue—urinary bladder cancer	0.00165	0.0238	CbGeAlD
Medroxyprogesterone Acetate—PGR—prostate gland—urinary bladder cancer	0.00158	0.0228	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—urethra—urinary bladder cancer	0.00156	0.0225	CbGeAlD
Medroxyprogesterone Acetate—AR—prostate gland—urinary bladder cancer	0.00126	0.0181	CbGeAlD
Medroxyprogesterone Acetate—ESR1—prostate gland—urinary bladder cancer	0.00124	0.0178	CbGeAlD
Medroxyprogesterone Acetate—PGR—epithelium—urinary bladder cancer	0.00116	0.0167	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—vagina—urinary bladder cancer	0.00115	0.0166	CbGeAlD
Medroxyprogesterone Acetate—PGR—smooth muscle tissue—urinary bladder cancer	0.00112	0.0161	CbGeAlD
Medroxyprogesterone Acetate—AR—seminal vesicle—urinary bladder cancer	0.00106	0.0153	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female reproductive system—urinary bladder cancer	0.000957	0.0138	CbGeAlD
Medroxyprogesterone Acetate—AR—epithelium—urinary bladder cancer	0.000925	0.0133	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—prostate gland—urinary bladder cancer	0.000911	0.0131	CbGeAlD
Medroxyprogesterone Acetate—ESR1—epithelium—urinary bladder cancer	0.000908	0.0131	CbGeAlD
Medroxyprogesterone Acetate—AR—smooth muscle tissue—urinary bladder cancer	0.000891	0.0128	CbGeAlD
Medroxyprogesterone Acetate—ESR1—smooth muscle tissue—urinary bladder cancer	0.000875	0.0126	CbGeAlD
Medroxyprogesterone Acetate—SHBG—vagina—urinary bladder cancer	0.000866	0.0125	CbGeAlD
Medroxyprogesterone Acetate—PGR—female reproductive system—urinary bladder cancer	0.000862	0.0124	CbGeAlD
Medroxyprogesterone Acetate—AR—renal system—urinary bladder cancer	0.000858	0.0124	CbGeAlD
Medroxyprogesterone Acetate—AR—urethra—urinary bladder cancer	0.000843	0.0122	CbGeAlD
Medroxyprogesterone Acetate—ESR1—renal system—urinary bladder cancer	0.000842	0.0121	CbGeAlD
Medroxyprogesterone Acetate—PGR—vagina—urinary bladder cancer	0.00078	0.0112	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—seminal vesicle—urinary bladder cancer	0.000771	0.0111	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lymph node—urinary bladder cancer	0.000745	0.0107	CbGeAlD
Medroxyprogesterone Acetate—Ethynodiol—ESR1—urinary bladder cancer	0.000707	0.485	CrCbGaD
Medroxyprogesterone Acetate—CYP2C8—renal system—urinary bladder cancer	0.000694	0.01	CbGeAlD
Medroxyprogesterone Acetate—AR—female reproductive system—urinary bladder cancer	0.000687	0.00991	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female reproductive system—urinary bladder cancer	0.000674	0.00972	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—epithelium—urinary bladder cancer	0.00067	0.00966	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—smooth muscle tissue—urinary bladder cancer	0.000645	0.00931	CbGeAlD
Medroxyprogesterone Acetate—AR—vagina—urinary bladder cancer	0.000621	0.00896	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—renal system—urinary bladder cancer	0.000621	0.00896	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—urethra—urinary bladder cancer	0.00061	0.0088	CbGeAlD
Medroxyprogesterone Acetate—ESR1—vagina—urinary bladder cancer	0.00061	0.00879	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—female reproductive system—urinary bladder cancer	0.000556	0.00801	CbGeAlD
Medroxyprogesterone Acetate—PGR—lymph node—urinary bladder cancer	0.000504	0.00727	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—vagina—urinary bladder cancer	0.000502	0.00725	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—female reproductive system—urinary bladder cancer	0.000498	0.00717	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—female reproductive system—urinary bladder cancer	0.000493	0.00712	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—renal system—urinary bladder cancer	0.00047	0.00678	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—vagina—urinary bladder cancer	0.00045	0.00649	CbGeAlD
Medroxyprogesterone Acetate—AR—lymph node—urinary bladder cancer	0.000402	0.00579	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—urinary bladder cancer	0.000394	0.00569	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—female reproductive system—urinary bladder cancer	0.000376	0.00543	CbGeAlD
Medroxyprogesterone Acetate—Fluoxymesterone—ESR1—urinary bladder cancer	0.000351	0.241	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—lymph node—urinary bladder cancer	0.000291	0.0042	CbGeAlD
Medroxyprogesterone Acetate—Drospirenone—PTGS2—urinary bladder cancer	0.000225	0.155	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—ESR1—urinary bladder cancer	0.000174	0.119	CrCbGaD
Medroxyprogesterone Acetate—Body temperature increased—Etoposide—urinary bladder cancer	6.79e-05	0.000399	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Doxorubicin—urinary bladder cancer	6.79e-05	0.000399	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Epirubicin—urinary bladder cancer	6.77e-05	0.000398	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Epirubicin—urinary bladder cancer	6.77e-05	0.000398	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Methotrexate—urinary bladder cancer	6.76e-05	0.000398	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Fluorouracil—urinary bladder cancer	6.76e-05	0.000398	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Methotrexate—urinary bladder cancer	6.75e-05	0.000397	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Cisplatin—urinary bladder cancer	6.72e-05	0.000395	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Epirubicin—urinary bladder cancer	6.72e-05	0.000395	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Methotrexate—urinary bladder cancer	6.72e-05	0.000395	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Doxorubicin—urinary bladder cancer	6.69e-05	0.000394	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Epirubicin—urinary bladder cancer	6.69e-05	0.000393	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Epirubicin—urinary bladder cancer	6.67e-05	0.000393	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Epirubicin—urinary bladder cancer	6.66e-05	0.000392	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Epirubicin—urinary bladder cancer	6.64e-05	0.000391	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	6.6e-05	0.000388	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Doxorubicin—urinary bladder cancer	6.58e-05	0.000387	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Methotrexate—urinary bladder cancer	6.57e-05	0.000386	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Doxorubicin—urinary bladder cancer	6.55e-05	0.000385	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Methotrexate—urinary bladder cancer	6.54e-05	0.000385	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Fluorouracil—urinary bladder cancer	6.54e-05	0.000385	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Epirubicin—urinary bladder cancer	6.53e-05	0.000384	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Methotrexate—urinary bladder cancer	6.52e-05	0.000384	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Methotrexate—urinary bladder cancer	6.49e-05	0.000382	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Cisplatin—urinary bladder cancer	6.41e-05	0.000377	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Epirubicin—urinary bladder cancer	6.4e-05	0.000377	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Methotrexate—urinary bladder cancer	6.39e-05	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Gemcitabine—urinary bladder cancer	6.39e-05	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—urinary bladder cancer	6.38e-05	0.000375	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Methotrexate—urinary bladder cancer	6.34e-05	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Gemcitabine—urinary bladder cancer	6.34e-05	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Gemcitabine—urinary bladder cancer	6.33e-05	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Epirubicin—urinary bladder cancer	6.33e-05	0.000372	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Etoposide—urinary bladder cancer	6.32e-05	0.000372	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Epirubicin—urinary bladder cancer	6.31e-05	0.000371	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Methotrexate—urinary bladder cancer	6.3e-05	0.000371	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Methotrexate—urinary bladder cancer	6.3e-05	0.000371	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—urinary bladder cancer	6.3e-05	0.000371	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Gemcitabine—urinary bladder cancer	6.3e-05	0.00037	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Epirubicin—urinary bladder cancer	6.29e-05	0.00037	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Fluorouracil—urinary bladder cancer	6.28e-05	0.00037	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—urinary bladder cancer	6.27e-05	0.000369	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—urinary bladder cancer	6.27e-05	0.000369	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Fluorouracil—urinary bladder cancer	6.23e-05	0.000367	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Fluorouracil—urinary bladder cancer	6.23e-05	0.000366	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—urinary bladder cancer	6.22e-05	0.000366	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Fluorouracil—urinary bladder cancer	6.19e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	6.19e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—urinary bladder cancer	6.17e-05	0.000363	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Methotrexate—urinary bladder cancer	6.17e-05	0.000363	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Etoposide—urinary bladder cancer	6.16e-05	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	6.16e-05	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Epirubicin—urinary bladder cancer	6.14e-05	0.000361	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—urinary bladder cancer	6.14e-05	0.000361	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Epirubicin—urinary bladder cancer	6.12e-05	0.00036	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Epirubicin—urinary bladder cancer	6.1e-05	0.000359	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Methotrexate—urinary bladder cancer	6.09e-05	0.000359	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Epirubicin—urinary bladder cancer	6.08e-05	0.000358	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Etoposide—urinary bladder cancer	6.07e-05	0.000357	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—urinary bladder cancer	6.04e-05	0.000355	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Epirubicin—urinary bladder cancer	5.98e-05	0.000352	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Gemcitabine—urinary bladder cancer	5.97e-05	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Cisplatin—urinary bladder cancer	5.96e-05	0.00035	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Epirubicin—urinary bladder cancer	5.93e-05	0.000349	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—urinary bladder cancer	5.92e-05	0.000349	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Cisplatin—urinary bladder cancer	5.91e-05	0.000348	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Cisplatin—urinary bladder cancer	5.9e-05	0.000347	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Epirubicin—urinary bladder cancer	5.9e-05	0.000347	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Epirubicin—urinary bladder cancer	5.9e-05	0.000347	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Etoposide—urinary bladder cancer	5.87e-05	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Fluorouracil—urinary bladder cancer	5.87e-05	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—urinary bladder cancer	5.86e-05	0.000345	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Methotrexate—urinary bladder cancer	5.85e-05	0.000344	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—urinary bladder cancer	5.84e-05	0.000344	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Methotrexate—urinary bladder cancer	5.82e-05	0.000343	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—urinary bladder cancer	5.82e-05	0.000342	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Epirubicin—urinary bladder cancer	5.81e-05	0.000342	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Epirubicin—urinary bladder cancer	5.79e-05	0.00034	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Epirubicin—urinary bladder cancer	5.77e-05	0.00034	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Epirubicin—urinary bladder cancer	5.73e-05	0.000337	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Epirubicin—urinary bladder cancer	5.7e-05	0.000336	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—urinary bladder cancer	5.69e-05	0.000334	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Methotrexate—urinary bladder cancer	5.68e-05	0.000334	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Etoposide—urinary bladder cancer	5.68e-05	0.000334	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Epirubicin—urinary bladder cancer	5.67e-05	0.000333	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—urinary bladder cancer	5.66e-05	0.000333	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Methotrexate—urinary bladder cancer	5.66e-05	0.000333	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	5.65e-05	0.000332	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—urinary bladder cancer	5.62e-05	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Cisplatin—urinary bladder cancer	5.57e-05	0.000327	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—urinary bladder cancer	5.54e-05	0.000326	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—urinary bladder cancer	5.49e-05	0.000323	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Epirubicin—urinary bladder cancer	5.47e-05	0.000322	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Methotrexate—urinary bladder cancer	5.46e-05	0.000321	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Etoposide—urinary bladder cancer	5.46e-05	0.000321	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—urinary bladder cancer	5.45e-05	0.000321	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—urinary bladder cancer	5.45e-05	0.000321	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Epirubicin—urinary bladder cancer	5.45e-05	0.000321	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Epirubicin—urinary bladder cancer	5.42e-05	0.000319	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Etoposide—urinary bladder cancer	5.41e-05	0.000318	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Etoposide—urinary bladder cancer	5.41e-05	0.000318	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Etoposide—urinary bladder cancer	5.38e-05	0.000316	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—urinary bladder cancer	5.38e-05	0.000316	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Methotrexate—urinary bladder cancer	5.36e-05	0.000316	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Methotrexate—urinary bladder cancer	5.36e-05	0.000316	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Methotrexate—urinary bladder cancer	5.36e-05	0.000316	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—urinary bladder cancer	5.35e-05	0.000315	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—urinary bladder cancer	5.34e-05	0.000314	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	5.33e-05	0.000313	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Epirubicin—urinary bladder cancer	5.32e-05	0.000313	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Methotrexate—urinary bladder cancer	5.3e-05	0.000312	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—urinary bladder cancer	5.3e-05	0.000312	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Epirubicin—urinary bladder cancer	5.3e-05	0.000312	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Epirubicin—urinary bladder cancer	5.29e-05	0.000311	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—urinary bladder cancer	5.28e-05	0.00031	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—urinary bladder cancer	5.24e-05	0.000309	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Epirubicin—urinary bladder cancer	5.21e-05	0.000307	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Methotrexate—urinary bladder cancer	5.18e-05	0.000305	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Epirubicin—urinary bladder cancer	5.18e-05	0.000305	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Methotrexate—urinary bladder cancer	5.14e-05	0.000302	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Epirubicin—urinary bladder cancer	5.11e-05	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Methotrexate—urinary bladder cancer	5.11e-05	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Etoposide—urinary bladder cancer	5.1e-05	0.0003	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—urinary bladder cancer	5.06e-05	0.000298	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Methotrexate—urinary bladder cancer	5.04e-05	0.000297	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—urinary bladder cancer	5.04e-05	0.000297	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.03e-05	0.000296	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Epirubicin—urinary bladder cancer	5.02e-05	0.000295	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Epirubicin—urinary bladder cancer	5.02e-05	0.000295	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Epirubicin—urinary bladder cancer	5.02e-05	0.000295	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—urinary bladder cancer	5.01e-05	0.000295	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Epirubicin—urinary bladder cancer	5e-05	0.000294	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Methotrexate—urinary bladder cancer	4.99e-05	0.000294	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.98e-05	0.000293	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Methotrexate—urinary bladder cancer	4.97e-05	0.000292	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Epirubicin—urinary bladder cancer	4.96e-05	0.000292	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—urinary bladder cancer	4.92e-05	0.000289	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Epirubicin—urinary bladder cancer	4.91e-05	0.000289	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—urinary bladder cancer	4.9e-05	0.000288	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Methotrexate—urinary bladder cancer	4.9e-05	0.000288	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—urinary bladder cancer	4.89e-05	0.000288	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Epirubicin—urinary bladder cancer	4.85e-05	0.000285	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—urinary bladder cancer	4.82e-05	0.000284	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Epirubicin—urinary bladder cancer	4.81e-05	0.000283	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Epirubicin—urinary bladder cancer	4.81e-05	0.000283	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Methotrexate—urinary bladder cancer	4.8e-05	0.000283	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—urinary bladder cancer	4.79e-05	0.000282	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Epirubicin—urinary bladder cancer	4.78e-05	0.000281	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Epirubicin—urinary bladder cancer	4.73e-05	0.000279	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—urinary bladder cancer	4.73e-05	0.000278	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Epirubicin—urinary bladder cancer	4.72e-05	0.000278	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Epirubicin—urinary bladder cancer	4.71e-05	0.000277	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Epirubicin—urinary bladder cancer	4.7e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	4.68e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Epirubicin—urinary bladder cancer	4.67e-05	0.000275	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Epirubicin—urinary bladder cancer	4.65e-05	0.000274	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Methotrexate—urinary bladder cancer	4.65e-05	0.000274	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—urinary bladder cancer	4.64e-05	0.000273	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—urinary bladder cancer	4.64e-05	0.000273	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—urinary bladder cancer	4.64e-05	0.000273	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—urinary bladder cancer	4.63e-05	0.000272	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Methotrexate—urinary bladder cancer	4.62e-05	0.000272	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4.61e-05	0.000271	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—urinary bladder cancer	4.59e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Epirubicin—urinary bladder cancer	4.59e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Methotrexate—urinary bladder cancer	4.58e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Methotrexate—urinary bladder cancer	4.57e-05	0.000269	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—urinary bladder cancer	4.54e-05	0.000267	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Methotrexate—urinary bladder cancer	4.53e-05	0.000266	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Epirubicin—urinary bladder cancer	4.5e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—urinary bladder cancer	4.49e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Methotrexate—urinary bladder cancer	4.47e-05	0.000263	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—urinary bladder cancer	4.45e-05	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	4.45e-05	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	4.44e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Methotrexate—urinary bladder cancer	4.43e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—urinary bladder cancer	4.42e-05	0.00026	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.38e-05	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—urinary bladder cancer	4.38e-05	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—urinary bladder cancer	4.37e-05	0.000257	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—urinary bladder cancer	4.36e-05	0.000256	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Epirubicin—urinary bladder cancer	4.35e-05	0.000256	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—urinary bladder cancer	4.35e-05	0.000256	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—urinary bladder cancer	4.32e-05	0.000254	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Epirubicin—urinary bladder cancer	4.32e-05	0.000254	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.3e-05	0.000253	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Epirubicin—urinary bladder cancer	4.29e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Epirubicin—urinary bladder cancer	4.28e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—urinary bladder cancer	4.24e-05	0.00025	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Methotrexate—urinary bladder cancer	4.24e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Epirubicin—urinary bladder cancer	4.24e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.2e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Epirubicin—urinary bladder cancer	4.18e-05	0.000246	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—urinary bladder cancer	4.16e-05	0.000245	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.15e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Epirubicin—urinary bladder cancer	4.15e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Epirubicin—urinary bladder cancer	4.11e-05	0.000242	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Methotrexate—urinary bladder cancer	4.08e-05	0.00024	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Methotrexate—urinary bladder cancer	4.06e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Methotrexate—urinary bladder cancer	4.06e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.06e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—urinary bladder cancer	4.03e-05	0.000237	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—urinary bladder cancer	4e-05	0.000235	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—urinary bladder cancer	3.97e-05	0.000234	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Epirubicin—urinary bladder cancer	3.96e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—urinary bladder cancer	3.96e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.93e-05	0.000231	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—urinary bladder cancer	3.92e-05	0.000231	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—urinary bladder cancer	3.87e-05	0.000228	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.84e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—urinary bladder cancer	3.84e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Epirubicin—urinary bladder cancer	3.82e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—urinary bladder cancer	3.81e-05	0.000224	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Epirubicin—urinary bladder cancer	3.8e-05	0.000224	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Epirubicin—urinary bladder cancer	3.8e-05	0.000224	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Methotrexate—urinary bladder cancer	3.79e-05	0.000223	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Methotrexate—urinary bladder cancer	3.69e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—urinary bladder cancer	3.67e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.64e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Methotrexate—urinary bladder cancer	3.64e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Epirubicin—urinary bladder cancer	3.54e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—urinary bladder cancer	3.54e-05	0.000208	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—urinary bladder cancer	3.52e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—urinary bladder cancer	3.52e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Methotrexate—urinary bladder cancer	3.52e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Epirubicin—urinary bladder cancer	3.45e-05	0.000203	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Epirubicin—urinary bladder cancer	3.4e-05	0.0002	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Methotrexate—urinary bladder cancer	3.4e-05	0.0002	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Epirubicin—urinary bladder cancer	3.29e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—ERCC2—urinary bladder cancer	3.29e-05	0.000387	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.28e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Methotrexate—urinary bladder cancer	3.27e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Methotrexate—urinary bladder cancer	3.24e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Methotrexate—urinary bladder cancer	3.24e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	3.23e-05	0.000381	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.23e-05	0.000381	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Methotrexate—urinary bladder cancer	3.22e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	3.21e-05	0.000378	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	3.21e-05	0.000378	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—urinary bladder cancer	3.19e-05	0.000188	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—GSTP1—urinary bladder cancer	3.19e-05	0.000375	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Epirubicin—urinary bladder cancer	3.18e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.17e-05	0.000374	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—urinary bladder cancer	3.15e-05	0.000185	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—MTHFR—urinary bladder cancer	3.09e-05	0.000364	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.08e-05	0.000363	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—TERT—urinary bladder cancer	3.08e-05	0.000363	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Epirubicin—urinary bladder cancer	3.06e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Methotrexate—urinary bladder cancer	3.05e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—urinary bladder cancer	3.05e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	3.04e-05	0.000358	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NAT1—urinary bladder cancer	3.04e-05	0.000358	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Epirubicin—urinary bladder cancer	3.03e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Epirubicin—urinary bladder cancer	3.03e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HDAC4—urinary bladder cancer	3.03e-05	0.000357	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Epirubicin—urinary bladder cancer	3.01e-05	0.000177	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.99e-05	0.000352	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.98e-05	0.000351	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—NCOR1—urinary bladder cancer	2.97e-05	0.00035	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—RBX1—urinary bladder cancer	2.96e-05	0.000349	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—TYMS—urinary bladder cancer	2.96e-05	0.000349	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	2.95e-05	0.000348	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—urinary bladder cancer	2.94e-05	0.000173	CcSEcCtD
Medroxyprogesterone Acetate—AR—Gene Expression—ESR2—urinary bladder cancer	2.93e-05	0.000345	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—NCOR1—urinary bladder cancer	2.93e-05	0.000345	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—GSTM1—urinary bladder cancer	2.93e-05	0.000345	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PTEN—urinary bladder cancer	2.91e-05	0.000343	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.91e-05	0.000343	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Epirubicin—urinary bladder cancer	2.86e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—urinary bladder cancer	2.83e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—FGFR3—urinary bladder cancer	2.83e-05	0.000333	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.81e-05	0.000331	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—HRAS—urinary bladder cancer	2.81e-05	0.000331	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Doxorubicin—urinary bladder cancer	2.81e-05	0.000165	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—urinary bladder cancer	2.8e-05	0.000165	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—GPX1—urinary bladder cancer	2.8e-05	0.00033	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	2.8e-05	0.00033	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—ERCC2—urinary bladder cancer	2.79e-05	0.000329	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Doxorubicin—urinary bladder cancer	2.79e-05	0.000164	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TSC1—urinary bladder cancer	2.79e-05	0.000328	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	2.78e-05	0.000328	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—EP300—urinary bladder cancer	2.78e-05	0.000327	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.77e-05	0.000327	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.77e-05	0.000327	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—ERCC2—urinary bladder cancer	2.75e-05	0.000324	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.75e-05	0.000324	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—S100B—urinary bladder cancer	2.72e-05	0.000321	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—JAG1—urinary bladder cancer	2.65e-05	0.000312	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—urinary bladder cancer	2.64e-05	0.000156	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	2.61e-05	0.000308	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—PPARG—urinary bladder cancer	2.59e-05	0.000306	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—SMC1A—urinary bladder cancer	2.59e-05	0.000305	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—MTHFR—urinary bladder cancer	2.59e-05	0.000305	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.58e-05	0.000304	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	2.55e-05	0.000301	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	2.55e-05	0.0003	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.55e-05	0.0003	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GLI1—urinary bladder cancer	2.54e-05	0.000299	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—MYC—urinary bladder cancer	2.52e-05	0.000297	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	2.5e-05	0.000295	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	2.49e-05	0.000294	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NAT1—urinary bladder cancer	2.48e-05	0.000292	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	2.48e-05	0.000292	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	2.45e-05	0.000289	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NCOR1—urinary bladder cancer	2.45e-05	0.000288	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.45e-05	0.000288	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.43e-05	0.000287	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CREBBP—urinary bladder cancer	2.41e-05	0.000283	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	2.37e-05	0.000279	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—ESR1—urinary bladder cancer	2.33e-05	0.000275	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	2.3e-05	0.000271	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	2.26e-05	0.000267	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—NCOR1—urinary bladder cancer	2.26e-05	0.000266	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—ESR2—urinary bladder cancer	2.26e-05	0.000266	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ESR2—urinary bladder cancer	2.22e-05	0.000262	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—RHOA—urinary bladder cancer	2.18e-05	0.000256	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TERT—urinary bladder cancer	2.16e-05	0.000254	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—S100B—urinary bladder cancer	2.15e-05	0.000253	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—PPARG—urinary bladder cancer	2.13e-05	0.000251	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—ERCC2—urinary bladder cancer	2.13e-05	0.000251	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PPARG—urinary bladder cancer	2.1e-05	0.000247	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—CREBBP—urinary bladder cancer	2.04e-05	0.000241	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	2.04e-05	0.00024	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CREBBP—urinary bladder cancer	2.02e-05	0.000237	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ERBB2—urinary bladder cancer	2.02e-05	0.000237	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FGFR3—urinary bladder cancer	1.98e-05	0.000233	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTGS2—urinary bladder cancer	1.97e-05	0.000232	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NCOR1—urinary bladder cancer	1.93e-05	0.000227	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.92e-05	0.000227	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ESR1—urinary bladder cancer	1.92e-05	0.000226	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—MYC—urinary bladder cancer	1.92e-05	0.000226	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.88e-05	0.000221	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.85e-05	0.000218	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TYMP—urinary bladder cancer	1.84e-05	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—ESR1—urinary bladder cancer	1.78e-05	0.000209	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.77e-05	0.000208	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—NCOR1—urinary bladder cancer	1.74e-05	0.000205	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RBX1—urinary bladder cancer	1.74e-05	0.000205	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CDKN1A—urinary bladder cancer	1.72e-05	0.000203	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.72e-05	0.000203	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTEN—urinary bladder cancer	1.72e-05	0.000202	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	1.72e-05	0.000202	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TERT—urinary bladder cancer	1.7e-05	0.0002	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CREBBP—urinary bladder cancer	1.69e-05	0.000198	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.67e-05	0.000196	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IGF1—urinary bladder cancer	1.66e-05	0.000196	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTGS2—urinary bladder cancer	1.65e-05	0.000194	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—EP300—urinary bladder cancer	1.64e-05	0.000193	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—ERCC2—urinary bladder cancer	1.64e-05	0.000193	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TSC1—urinary bladder cancer	1.63e-05	0.000193	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.63e-05	0.000192	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.63e-05	0.000192	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—PPARG—urinary bladder cancer	1.62e-05	0.000191	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	1.61e-05	0.00019	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—SRC—urinary bladder cancer	1.59e-05	0.000188	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FGFR3—urinary bladder cancer	1.56e-05	0.000184	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—CREBBP—urinary bladder cancer	1.56e-05	0.000183	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—JAG1—urinary bladder cancer	1.56e-05	0.000183	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—RHOA—urinary bladder cancer	1.52e-05	0.00018	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ESR1—urinary bladder cancer	1.52e-05	0.000179	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.5e-05	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.5e-05	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.49e-05	0.000176	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—MYC—urinary bladder cancer	1.48e-05	0.000174	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	1.46e-05	0.000172	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.44e-05	0.00017	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTEN—urinary bladder cancer	1.44e-05	0.00017	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.44e-05	0.000169	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MYC—urinary bladder cancer	1.43e-05	0.000168	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ERBB2—urinary bladder cancer	1.41e-05	0.000166	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—EGFR—urinary bladder cancer	1.4e-05	0.000165	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—EP300—urinary bladder cancer	1.37e-05	0.000162	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.36e-05	0.00016	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ESR1—urinary bladder cancer	1.35e-05	0.000159	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.34e-05	0.000158	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CXCL8—urinary bladder cancer	1.34e-05	0.000158	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.33e-05	0.000157	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.33e-05	0.000157	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CREBBP—urinary bladder cancer	1.33e-05	0.000157	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.32e-05	0.000156	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KRAS—urinary bladder cancer	1.32e-05	0.000155	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IGF1—urinary bladder cancer	1.31e-05	0.000155	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.29e-05	0.000152	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL2—urinary bladder cancer	1.28e-05	0.000151	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.27e-05	0.00015	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.27e-05	0.00015	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—S100B—urinary bladder cancer	1.26e-05	0.000148	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PPARG—urinary bladder cancer	1.25e-05	0.000147	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CCND1—urinary bladder cancer	1.25e-05	0.000147	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.24e-05	0.000146	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PPARG—urinary bladder cancer	1.23e-05	0.000145	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MYC—urinary bladder cancer	1.21e-05	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MMP9—urinary bladder cancer	1.21e-05	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.21e-05	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PTEN—urinary bladder cancer	1.2e-05	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—RHOA—urinary bladder cancer	1.2e-05	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—CREBBP—urinary bladder cancer	1.2e-05	0.000141	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	1.18e-05	0.000139	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.17e-05	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EP300—urinary bladder cancer	1.15e-05	0.000135	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.13e-05	0.000133	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HRAS—urinary bladder cancer	1.12e-05	0.000132	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SRC—urinary bladder cancer	1.12e-05	0.000131	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ERBB2—urinary bladder cancer	1.11e-05	0.000131	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.08e-05	0.000128	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.08e-05	0.000128	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.08e-05	0.000127	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.07e-05	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CXCL8—urinary bladder cancer	1.06e-05	0.000124	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.05e-05	0.000124	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.04e-05	0.000123	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.04e-05	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL2—urinary bladder cancer	1.01e-05	0.000119	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MYC—urinary bladder cancer	1e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TERT—urinary bladder cancer	9.99e-06	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TYMP—urinary bladder cancer	9.89e-06	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCND1—urinary bladder cancer	9.83e-06	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EGFR—urinary bladder cancer	9.78e-06	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MMP9—urinary bladder cancer	9.55e-06	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1A—urinary bladder cancer	9.51e-06	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTEN—urinary bladder cancer	9.49e-06	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MYC—urinary bladder cancer	9.24e-06	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KRAS—urinary bladder cancer	9.24e-06	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FGFR3—urinary bladder cancer	9.16e-06	0.000108	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.09e-06	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EP300—urinary bladder cancer	9.05e-06	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	8.96e-06	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.94e-06	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SRC—urinary bladder cancer	8.8e-06	0.000104	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NQO1—urinary bladder cancer	8.74e-06	0.000103	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.66e-06	0.000102	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.48e-06	9.99e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TYMS—urinary bladder cancer	8.33e-06	9.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	8.23e-06	9.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	8.23e-06	9.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—urinary bladder cancer	8.21e-06	9.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MYC—urinary bladder cancer	7.89e-06	9.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GPX1—urinary bladder cancer	7.88e-06	9.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HRAS—urinary bladder cancer	7.85e-06	9.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CREBBP—urinary bladder cancer	7.8e-06	9.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	7.74e-06	9.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—RRM2—urinary bladder cancer	7.72e-06	9.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EGFR—urinary bladder cancer	7.72e-06	9.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF1—urinary bladder cancer	7.7e-06	9.07e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.39e-06	8.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KRAS—urinary bladder cancer	7.29e-06	8.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	7.29e-06	8.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	7.27e-06	8.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	7.15e-06	8.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ENO2—urinary bladder cancer	7.15e-06	8.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MYC—urinary bladder cancer	7.12e-06	8.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RHOA—urinary bladder cancer	7.06e-06	8.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.05e-06	8.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MYC—urinary bladder cancer	7.01e-06	8.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.94e-06	8.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TYMS—urinary bladder cancer	6.78e-06	7.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	6.7e-06	7.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	6.7e-06	7.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB2—urinary bladder cancer	6.53e-06	7.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—urinary bladder cancer	6.48e-06	7.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GPX1—urinary bladder cancer	6.41e-06	7.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	6.3e-06	7.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HRAS—urinary bladder cancer	6.2e-06	7.3e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CXCL8—urinary bladder cancer	6.2e-06	7.3e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL2—urinary bladder cancer	5.92e-06	6.97e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.92e-06	6.97e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PPARG—urinary bladder cancer	5.9e-06	6.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCND1—urinary bladder cancer	5.77e-06	6.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.76e-06	6.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	5.67e-06	6.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MMP9—urinary bladder cancer	5.6e-06	6.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.58e-06	6.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTEN—urinary bladder cancer	5.57e-06	6.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EP300—urinary bladder cancer	5.31e-06	6.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SRC—urinary bladder cancer	5.17e-06	6.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.81e-06	5.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.8e-06	5.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	4.64e-06	5.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MYC—urinary bladder cancer	4.63e-06	5.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	4.61e-06	5.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EGFR—urinary bladder cancer	4.53e-06	5.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.47e-06	5.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.42e-06	5.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.42e-06	5.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KRAS—urinary bladder cancer	4.28e-06	5.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.23e-06	4.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.15e-06	4.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTEN—urinary bladder cancer	4.05e-06	4.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.9e-06	4.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—EP300—urinary bladder cancer	3.86e-06	4.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—urinary bladder cancer	3.8e-06	4.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.78e-06	4.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HRAS—urinary bladder cancer	3.64e-06	4.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3.29e-06	3.88e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.17e-06	3.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—EP300—urinary bladder cancer	3.14e-06	3.7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.04e-06	3.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.49e-06	2.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.17e-06	2.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.07e-06	2.44e-05	CbGpPWpGaD
